Molecular Docking based analysis to elucidate the DNA Topoisomerase IIβ as the potential target for the Ganoderic acid, A natural therapeutic agent in cancer therapy.

Clicks: 379
ID: 12320
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #6 of 126 articles by views in current computer-aided drug design

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 126 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Intermediate covalent complex of DNA-Topoisomerase II enzyme is a most promising target of the anticancer drugs to induce apoptosis in cancer cells. Currently, Anticancer drug and chemotherapy are facing major challenges i.e., drug resistance, chemical instability and, dose-limiting side effect. Therefore, in this study, natural therapeutic agents (series of Ganoderic acids), were used for the molecular docking simulation against Human DNA-Topoisomerase IIbeta complex (PDB ID:3QX3).Molecular docking studies were performed on a 50 series of ganoderic acids reported in the NCBI-PubChem database and FDA approved anti-cancer drugs, to find out binding energy, an interacting residue at the active site of Human DNA-Topoisomerase IIbeta and compare with the molecular arrangements of interacting residue of etoposide with the Human DNA topoisomerase IIbeta. The Autodock 4.2 were used for the molecular docking and pharmacokinetic and toxicity studies were performed for the analysis of physicochemical properties and to check the toxicity effects. Discovery studio software was used for the visualization and analysis of docked pose.Ganoderic acid GS-1 and Ganoderic acid A were found to be a more suitable competitor inhibitor among the ganoderic acid series with appropriate binding energy, pharmacokinetic profile and no toxicity effects. The interacting residue (Met782, DC-8, DC-11 and, DA-12) shared a chemical resemblance with the interacting residue of etoposide present at the active site of human topoisomerase IIbeta receptor.
Reference Key
kaushal2019molecularcurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kaushal, Sharma K;Brijendra, Singh;Mujwar, Somdutt;Prakash, Bisen S;
Journal current computer-aided drug design
Year 2019
DOI
10.2174/1573409915666190820144759
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.